Skip Navigation

Failure to Launch: Barriers to Biosimilar Market Adoption, $2.2 Billion in Lost Savings

September 18, 2019

This report looks at reasons behind the less than robust market for the nine biosimilar drugs now approved for patient use.

   The report, released by the Biosimilars Council in September 2019,  is the second part of a 2015 white paper that detailed how patent abuses by biologic drug makers have cost the U.S. health care system $7.6 million in savings since 2015. The new report looks specifically at the 9 biosimilar drugs now on the market and calculates an additional $2.2 billion in lost savings, not just from marketing tactics by drug makers trying to corner the market from lower cost alternatives, but inadequate incentives to expand use and insufficient information for patients